Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni to Board of Directors
SAN DIEGO, Dec. 17, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced the appointment of Manmeet S. Soni as a non-executive director. Mr. Soni is a highly accomplished senior finance executive with extensive experience in the life sciences industry.
"Manmeet brings deep financial and business expertise to the board, and we are thrilled to welcome him," said Tina Nova, Chairman of the Board of Directors of Arena. "His leadership abilities and senior finance experience within the life sciences industry will be instrumental as we strategically advance Arena towards its next stage of growth."
Mr. Soni has served as Senior Vice President, Chief Financial Officer of Alnylam Pharmaceuticals, Inc. since May 2017. From March 2016 to February 2017, he was Executive Vice President, Chief Financial Officer and Treasurer of ARIAD Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, when ARIAD was acquired by Takeda Pharmaceutical Company Limited. Previously, Mr. Soni served as Chief Financial Officer of Pharmacyclics, Inc., a publicly-held biopharmaceutical company, until its acquisition by AbbVie, Inc. in May 2015. He first joined Pharmacyclics in September 2012 as corporate controller and served in various increasingly senior roles prior to being appointed Chief Financial Officer and Treasurer in February 2014. Prior to joining Pharmacyclics, Mr. Soni worked at ZELTIQ Aesthetics Inc., a publicly held medical technology company, as well as PricewaterhouseCoopers, in the Life Science and Venture Capital Group and PricewaterhouseCoopers India, providing audit and assurance services. Mr. Soni currently serves as director of Pulse Biosciences, Inc. He is a certified public accountant and completed his Chartered Accountancy from the Institute of Chartered Accountants of India.
About Arena
Pharmaceuticals
Arena
Pharmaceuticals is driven to deliver novel, transformational
medicines with optimized pharmacology and pharmacokinetics to
patients globally. Arena's proprietary pipeline includes multiple
potentially first- or best-in-class assets with broad clinical
utility. Etrasimod (APD334), with potential
utility in a broad range of immune and inflammatory conditions, is
being evaluated in later-stage clinical programs in ulcerative
colitis (UC) and Crohn's disease, as well as in programs for
primary biliary cholangitis (PBC) and atopic dermatitis. Ralinepag (APD811) is being evaluated in a
Phase 3 program for pulmonary arterial hypertension (PAH). Arena is
also evaluating olorinab (APD371) in a Phase 2 program for
gastrointestinal pain. Arena continues to assess other earlier
research and development stage drug candidates, including APD418
for decompensated heart failure.
In addition, Arena has several partnerships including with Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries), Boehringer Ingelheim International GmbH (undisclosed target - preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® - marketed product).
Forward-Looking Statements
Certain
statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. These
forward-looking statements may be accompanied by words such as
"will," "driven to," "potentially," "potential," or words of
similar meaning, or they may be identified by the fact that they do
not relate strictly to historical or current facts. Such
forward-looking statements include, without limitation, statements
about Mr. Soni's expected contribution; Arena's potential strategic
advancement toward its next stage of growth; and Arena's drive,
focus, goals, strategy, clinical and research and development
programs, and collaborations. For such statements, Arena claims the
protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from Arena's
expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include the
timing and outcome of research, development and regulatory review
is uncertain; clinical programs may not proceed at the time or in
the manner expected or at all; results of clinical trials and other
studies are subject to different interpretations and may not be
predictive of future results; and other risks related to developing
and commercializing drugs; as well as those factors disclosed in
Arena's filings with the Securities and Exchange
Commission (SEC), including but not limited to Arena's
Quarterly Report on Form 10-Q for the quarter ended September
30, 2018, which was filed with the SEC on November
8, 2018. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
[email protected]
858.210.3636
Media Contact:
Matt Middleman,
MD
LifeSci Public Relations
[email protected]
646.627.8384
View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-appoints-experienced-life-sciences-industry-finance-executive-manmeet-s-soni-to-board-of-directors-300765983.html